Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Yellowknifer69on Aug 07, 2020 10:00am
374 Views
Post# 31378297

Marketing

MarketingHello and good morning Longs:

Happy Friday!  Hope you are all able to make it a great Day!

Just wanted to chime in on the latest NR.  IMO, companies typically hire external PR firms when they don't have the band width to market their product / services themselves.

On that note I thought Antibe just hired DR. Rami Batal to guide commercial strategy? So there would appear to be a level of redundancy there?

Furthemore, if Antibe has spent the last ten years working diligently to solve a 100 year problem of GI bleeding - then I am fairly certain that every major Pharma is aware that we have solved the problem with Otena?

My experience with big Pharma suggests that this is a very aggressive industry, albeit a small one.  The competition is fierce and no stone goes unturned to get a leg up on your buddy who runs your competitor.  

So, if you are still following my thread - it doesn't really make a huge amount of sense to spend the money to market what everyone already knows.  Just let your all star new commercial guy do that?

Based on that, my bet is that they needed a company that is good at 'encouraging a big pharma to drink the coolaid" because the reaction to Phase 2 has been muted at best? thoughts?

Stay long boys,

Yellowknifer


Bullboard Posts